Matinas BioPharma Holdings financials
$2.53−92.97%
Close Sep 28, 2026 · split-adjustedToday's change is unusually large and no split is on record yet; it may reflect an unadjusted corporate action.
Revenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.1M | $3.2M | $33.0K | $158.3K | $89.8K | $119.8K | $149.7K |
| Gross profit | $0.00 | $0.00 | $1.1M | $3.2M | $33.0K | $158.3K | $89.8K | $119.8K | $149.7K |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$7.0M | -$24.6M | -$23.8M | -$24.6M | -$24.7M | -$24.2M | -$18.9M | -$14.6M | -$16.5M |
| Net income | -$11.0M | -$24.3M | -$22.9M | -$21.0M | -$23.7M | -$23.2M | -$18.3M | -$15.0M | -$32.8M |
| Net margin | — | — | −2093.2% | −658.6% | −71754.5% | −14678.1% | −20372.3% | −12516.2% | −21936.6% |
| Diluted EPS | $-30.00 | $-74.70 | $-79.20 | $-75.00 | $-82.50 | $-90.00 | $-97.50 | $-112.50 | $-270.00 |
| EBITDA | -$6.9M | -$19.8M | -$23.4M | -$23.7M | -$24.5M | -$23.5M | -$18.7M | -$14.4M | -$16.4M |
| Operating cash flow | -$7.0M | -$15.9M | -$15.3M | -$19.2M | -$15.2M | -$17.4M | -$14.1M | -$10.3M | -$11.5M |
| Free cash flow | -$7.0M | -$15.9M | -$15.5M | -$20.0M | -$15.5M | -$17.4M | -$14.5M | -$10.9M | -$12.4M |
| Diluted shares | 0.4M | 0.3M | 0.3M | 0.3M | 0.3M | 0.3M | 0.2M | 0.1M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.0M | $7.3M | $4.8M | $6.8M | $21.0M | $12.4M |
| Short-term investments | $0.00 | $0.00 | $9.0M | $21.9M | $28.6M | $46.2M |
| Total debt | $7.0K | $17.0K | $23.0K | $29.0K | $24.0K | $54.5K |
| Total assets | $7.2M | $12.6M | $25.1M | $44.8M | $61.3M | $71.0M |
| Total liabilities | $2.4M | $5.1M | $5.9M | $8.2M | $8.8M | $7.2M |
| Shareholders' equity | $4.8M | $7.6M | $19.2M | $36.6M | $52.5M | $63.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology